



## PRESS RELEASE

### PAION ANNOUNCES ATTENDANCE AT FOUR UPCOMING CONFERENCES

Aachen (Germany), 07 February 2019 – The specialty pharma company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces its participation in four upcoming conferences. PAION representatives will be available for one-on-one meetings at these events.

#### 2019 BIO CEO & Investor Conference

11 – 12 February 2019  
New York Marriott Marquis  
New York, U.S.

<https://www.bio.org/events/bio-ceo-investor-conference>

#### 13th ODDO BHF German Conference

19 – 20 February 2019  
The Westin Grand Hotel  
Frankfurt am Main, Germany

#### Bio-Europe Spring

25 – 27 March 2019  
Messe Wien Exhibition and Congress Center  
Vienna, Austria

<https://ebdgroup.knect365.com/bioeurope-spring/>

#### Invest Stuttgart

05 – 06 April 2019  
Meet us in hall 4, booth 4D52  
Messe Stuttgart  
Stuttgart, Germany

<https://www.messe-stuttgart.de/invest>

###

#### **About PAION**

PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs for out-patient and hospital-based sedation, anesthesia and critical care services. PAION's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate for which PAION has completed the clinical development for use in procedural sedation in the U.S. Outside the U.S., PAION is currently focused on the development of remimazolam for general anesthesia. Development of remimazolam for intensive care unit (ICU) sedation is also part of the longer-term life-cycle plan for remimazolam.

PAION's vision is to become an acknowledged “PAIONeer” in sedation and anesthesia. PAION is headquartered in Aachen (Germany) with an additional site in Cambridge (United Kingdom).

**PAION Contact**

Ralf Penner  
Vice President Investor Relations/Public Relations  
PAION AG  
Martinstrasse 10-12  
52062 Aachen – Germany  
Phone: +49 241 4453-152  
E-mail: [r.penner@paion.com](mailto:r.penner@paion.com)  
[www.paion.com](http://www.paion.com)

**Disclaimer:**

This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments.